SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 6, 2001
(December 5, 2001)
ENDO PHARMACEUTICALS HOLDINGS INC.
-------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 39040 13-4022871
-------------------------------------------------------------------------------
(State or other (Commission File Number) (I.R.S. Employer
jurisdiction of Identification No.)
incorporation)
100 Painters Drive
Chadds Ford, Pennsylvania 19317
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(610) 558-9800
-------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
N/A
-------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
Exhibit Number Description
99.1 Press release issued by Endo Pharmaceuticals Holdings
Inc. on December 5, 2001
99.2 Certain pages from the Offer to Purchase on Schedule TO
filed by Endo Pharmaceuticals Holdings Inc. on December
5, 2001 with the Securities and Exchange Commission
Item 9. Regulation FD Disclosure.
On December 5, 2001, the Registrant commenced a self
tender offer to purchase up to 13,500,000 of its outstanding Class A
Transferable Warrants (Nasdaq: ENDPW) and any and all of its outstanding
Class B Non-Transferable Warrants. The Registrant is offering to purchase
the Warrants at a purchase price of $0.75 per Warrant. The offer is
scheduled to expire at 12:00 midnight, New York City time, on January 14,
2002, unless the Company elects to extend the offer. The offer is subject
to various conditions described in the Offer to Purchase. In connection
with the offer, the Registrant issued a press release, a copy of which is
filed herewith as Exhibit 99.1 and is incorporated herein by reference. In
addition, filed herewith as Exhibit 99.2, and incorporated herein by
reference, are certain pages of the Offer to Purchase.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)
By: /s/ CAROL A. AMMON
-----------------------------------
Name: Carol A. Ammon
Title: President & Chief Executive
Officer
Dated: December 6, 2001
INDEX TO EXHIBITS
Exhibit No. Description
99.1 Press release issued by Endo Pharmaceuticals Holdings Inc.
on December 5, 2001
99.2 Certain pages from the Offer to Purchase on Schedule TO
filed by Endo Pharmaceuticals Holdings Inc. on December 5,
2001 with the Securities and Exchange Commission